UBIVAC, INC. — SEC Form D Filing

UBIVAC, INC. filed an SEC Form D on August 26, 2026, reporting $80K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
August 26, 2026
Amount reported
$80K
Round stage
Series B+
Industry
Biotechnology
Website
https://www.ubivac.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Many patients with advanced cancer lack immunity to their own cancer, which causes standard therapies and current immunotherapies to fail in providing extended benefit. Cancer cells are often not recognized as abnormal by the immune system, preventing them from being targeted and destroyed.

Solution

UbiVac is developing DPV-001, a clinical-stage "Dark Matter" cancer immunotherapy that contains newly discovered non-mutated shared alternative cancer neoantigens to educate and activate the immune system. This off-the-shelf vaccine aims to induce strong immune responses against cancer cells, including those not recognized by the immune system, improving response rates and potentially offering cures in combination with other therapies.

Why now

Recent breakthroughs (since 2021) in understanding the 'Dark Genome' and shared non-mutated alternative cancer neoantigens provide new targets, enabling the development of more effective, off-the-shelf universal cancer vaccines.

Verdict

Investors backed this because it presented a clinical-stage asset leveraging a novel biological hypothesis within a high-value therapeutic area, not because the amount raised indicated broad market confidence or competitive pricing pressure. The implicit bet was on the 'Dark Matter' neoantigen approach yielding superior immune responses compared to existing immunotherapies, particularly in hard-to-treat cancers. This upside was limited by the significant technical and regulatory hurdles inherent in novel oncology drug development, requiring substantial follow-on capital.

Source: SEC EDGAR Form D filing